(CIDRAP News) The first wave of H1N1 vaccine will probably consist of 3.4 million doses of MedImmune's nasal-spray product and is likely to reach providers the first week in October, federal health officials said today.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Feb 20, 2007 (CIDRAP News) Because of changes in the influenza viruses now in circulation, the World Health Organization (WHO) has recommended changing one of the three viral strains to be used in flu vaccines in the Northern Hemisphere next fall and winter.
(CIDRAP News) FluLaval has become the fifth influenza vaccine licensed by the US Food and Drug Administration (FDA) for use during the upcoming flu season, the FDA announced today.
FluLaval, produced by ID Biomedical Corp. of Quebec, a subsidiary of GlaxoSmithKline (GSK), has been marketed in Canada under the brand name Fluviral since 2001. It was granted fast-track review status by the FDA in July 2005.